Inventor · disambiguated record
Martin Lee Stockley
Also filed as: STOCKLEY MARTIN · STOCKLEY MARTIN LEE
32 granted patents·10 pending applications·52 citations·filing 2005–2022
95Inventor score
Top patents by PatentIndex Score
42 records- 0194US9926307B2CompoundsMISSION THERAPEUTICS LTD·Filed 2015·Granted Mar 27, 2018·14 cites·16 claims
- 0293US10343992B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2016·Granted Jul 9, 2019·7 cites·2 claims
- 0392US10689345B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·4 cites·14 claims
- 0489US10392380B2CompoundsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 27, 2019·6 cites·17 claims
- 0587US11130748B2CompoundsMISSION THERAPEUTICS LTD·Filed 2016·Granted Sep 28, 2021·3 cites·12 claims
- 0687US10774078B2CompoundsMISSION THERAPEUTICS LTD·Filed 2019·Granted Sep 15, 2020·2 cites·10 claims
- 0786US11472798B2CompoundsMISSION THERAPEUTICS LTD·Filed 2020·Granted Oct 18, 2022·1 cites·11 claims
- 0885US10640498B2CompoundsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 5, 2020·6 cites·17 claims
- 0983US11390584B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Jul 19, 2022·1 cites·14 claims
- 1081US11993595B2CompoundsMISSION THERAPEUTICS LTD·Filed 2022·Granted May 28, 2024·0 cites·10 claims
- 1178US2022251041A11-cyano-pyrrolidine compounds as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1275US10654846B2Autotaxin inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted May 19, 2020·2 cites·2 claims
- 1373US10669234B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2016·Granted Jun 2, 2020·1 cites·15 claims
- 1473US8202858B2Vasopressin V1a antagonistsBATT ANDRZEJ ROMAN·Filed 2005·Granted Jun 19, 2012·4 cites·29 claims
- 1572US10683269B22-cyanoisoindoline derivatives for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 16, 2020·1 cites·15 claims
- 1670US11066365B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 20, 2021·0 cites·14 claims
- 1770US11053198B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·0 cites·4 claims
- 1870US2022106315A1Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1968US11958833B2CompoundsMISSION THERAPEUTICS LTD·Filed 2021·Granted Apr 16, 2024·0 cites·14 claims
- 2068US11945797B21-cyano-pyrrolidine derivatives as dub inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Granted Apr 2, 2024·0 cites·15 claims
- 2166US11236092B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Feb 1, 2022·0 cites·10 claims
- 2260US11319287B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·0 cites·15 claims
- 2355US2024425511A1Heterocyclic compounds for use in the treatment of cancerARTIOS PHARMA LTD·Filed 2022·Application pending·0 cites
- 2455US2025230165A1Heterocyclic compounds for use in the treatment of cancerARTIOS PHARMA LTD·Filed 2022·Application pending·0 cites
- 2555US2025241926A1Heterocyclic compounds for use in the treatment of cancerARTIOS PHARMA LTD·Filed 2022·Application pending·0 cites
- 2654US11453666B2Autotaxin inhibitory compoundsCANCER RESEARCH TECH LTD·Filed 2020·Granted Sep 27, 2022·0 cites·20 claims
- 2754US2023312580A11-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosisMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2853US10654853B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 19, 2020·0 cites·10 claims
- 2948US11352339B21-cyano-pyrrolidine derivatives as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 7, 2022·0 cites·15 claims
- 3047US2024166623A1Novel processARTIOS PHARMA LTD·Filed 2022·Application pending·0 cites
- 3146US11414402B2Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 16, 2022·0 cites·14 claims
- 3246US10927110B2Cyano-subtituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Feb 23, 2021·0 cites·16 claims
- 3344US11059809B2Substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Jul 13, 2021·0 cites·16 claims
- 3443US11370784B2Cyano-substituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 28, 2022·0 cites·14 claims
- 3542US11084821B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Aug 10, 2021·0 cites·19 claims
- 3641US11014912B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted May 25, 2021·0 cites·17 claims
- 3741US2021002262A1Cyanopyrrolidines as usp30 inhibitors and fibrosis treatmentMISSION THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3840US11306096B24,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Apr 19, 2022·0 cites·11 claims
- 3940US11091488B21-cyano-pyrrolidine derivatives as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2016·Granted Aug 17, 2021·0 cites·18 claims
- 4040US2012101082A1Vasopressin v1a antagonistsBATT ANDRZEJ ROMAN·Filed 2011·Application pending·0 cites
- 4138US2022259174A1Deuterated compounds for use in the treatment of cancerARTIOS PHARMA LTD·Filed 2020·Application pending·0 cites
- 4236US12358886B2Heterocyclic compounds for use in the treatment of cancerARTIOS PHARMA LTD·Filed 2019·Granted Jul 15, 2025·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Martin Lee Stockley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →